SGO | Conference

SGO 2019: Maintenance Rucaparib Effective for All Age Groups in Ovarian Cancer

March 21, 2019

The results of a post-hoc exploratory analysis of the phase III ARIEL3 trial were promising.

SGO 2019: TWiST Backs Benefits of PARP Inhibitor in Ovarian Cancer

March 21, 2019

The TWiST analysis of the phase III ENGOT-OV16/NOVA trial evaluated the time without symptoms or toxicity for niraparib vs placebo in patients with recurrent ovarian cancer.

SGO 2019: Dendritic Cell–Based Immunotherapy Shows “Dramatic” Response for Ovarian Cancer

March 20, 2019

The phase II trial evaluated dendritic cell–based immunotherapy with concomitant administration of chemotherapy vs chemotherapy alone.